Clinical trial NCT07015255: Assessing the Burden of Respiratory Syncytial Virus (RSV)
Official title: Assessing the Burden of Respiratory Syncytial Virus (RSV): the Assessment of the Burden of Respiratory Syncytial Virus (RSV) Across Different Age Groups and Risk Factors
Study type: OBSERVATIONAL
Overall status: NOT_YET_RECRUITING
Conditions: Respiratory Syncytial Virus (RSV) Infection
Acute Lower Respiratory Tract Infections
Bronchiolitis
Pneumonia
Chronic Respiratory Conditions
Keywords: Respiratory Syncytial Virus
RSV
RSV Infection
RSV in Infants
RSV in Adults
RSV Hospitalization
RSV Epidemiology
RSV Burden
RSV Risk Factors
Retrospective Study
Observational Study
ICU Admissions
RSV Mortality
RSV Cost Analysis
RSV Complications
Asthma and RSV
Bronchiolitis
Pneumonia
Recurrent Wheezing
RSV Surveillance
RSV-Related Comorbidities
Lead sponsor: Abu Dhabi Health Services Company
Sponsor class: OTHER_GOV
First posted: 2025-06-11
Enrollment: 1500
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study includes all patients of any age who have a laboratory-confirmed diagnosis of Respiratory Syncytial Virus (RSV) infection recorded in the SEHA electronic medical records between January 2018 and December 2024. The population spans from newborn infants to elderly adults, including those with underlying medical conditions such as chronic lung disease, heart disease, immunosuppression, and other comorbidities that may influence RSV severity. Both hospitalized patients and those diagnosed in outpatient settings within SEHA healthcare facilities are included. The study aims to represent the full spectrum of RSV disease burden, clinical outcomes, risk factors, long-term health impacts, and healthcare costs across diverse demographic groups in the UAE.

Brief summary: This study examines the impact of Respiratory Syncytial Virus (RSV) on people of all ages, from infants to the elderly. It uses hospital records collected between January 2018 and December 2024 to understand:

* How often does RSV occur
* Who is most at risk
* The long-term and financial effects of RSV

Detailed description: This study is designed to analyze the impact of Respiratory Syncytial Virus (RSV) across different age groups. It focuses on how often RSV occurs, who is most at risk, and its long-term and financial effects. The study uses existing hospital records from SEHA facilities between January 2018 and December 2024. This is a retrospective observational study, meaning no new tests or treatments are given. Researchers look at medical records from past patients who were diagnosed with RSV. Anonymized data is collected from SEHA's Electronic Medical Records (EMR) and laboratory systems. Only patients with confirmed RSV infections are included.

Eligibility criteria: Inclusion Criteria:

* Patients of all ages with a confirmed diagnosis of RSV infection
* Patients admitted to a SEHA hospital or healthcare facility between January 2018 and December 2024
* Patients with documented data in the SEHA electronic medical record (EMR) system

Exclusion Criteria:

* Patients with suspected RSV infection that is not laboratory-confirmed
* Patients without sufficient data in the SEHA EMR system

Primary outcomes:
measure: Burden of RSV Infection Across All Age Groups
timeFrame: January 2018 - December 2024
Secondary outcomes:
measure: Identification of Risk Factors for Severe RSV Infection
timeFrame: January 2018 - December 2024
measure: Proportion of Hospital Admissions Due to RSV
timeFrame: January 2018 - December 2024
measure: ICU Admission Rates for RSV-Infected Patients
timeFrame: January 2018 - December 2024
measure: Financial Burden of RSV Infection
timeFrame: January 2018 - December 2024
measure: Incidence of Recurrent Wheezing and Asthma Diagnosis Following RSV Infection
timeFrame: Up to 12 months post-infection
measure: RSV-Associated Mortality Rates
timeFrame: January 2018 - December 2024
measure: Long-Term Respiratory Outcomes Following RSV Infection
timeFrame: Up to 12 months post-infection
Other outcomes:
Locations:
city: Abu Dhabi
country: United Arab Emirates
facility: Sheikh Khalifa Medical City (Abu Dhabi Health Research Centre), SEHA
Study officials:
affiliation: Abu Dhabi Health Services Company-SEHA
name: Salah Eldin Hussein, MD
role: STUDY_DIRECTOR
affiliation: Abu Dhabi Health Services Company-SEHA
name: Nawal Alkaabi, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Felton DA. A time of 'firsts'. J Prosthodont. 2004 Mar;13(1):1-2. doi: 10.1111/j.1532-849X.2004.04011.x. No abstract available.
citation: Zhou H, Thompson WW, Viboud CG, Ringholz CM, Cheng PY, Steiner C, Abedi GR, Anderson LJ, Brammer L, Shay DK. Hospitalizations associated with influenza and respiratory syncytial virus in the United States, 1993-2008. Clin Infect Dis. 2012 May;54(10):1427-36. doi: 10.1093/cid/cis211. Epub 2012 Apr 10.
citation: Hall CB, Weinberg GA, Iwane MK, Blumkin AK, Edwards KM, Staat MA, Auinger P, Griffin MR, Poehling KA, Erdman D, Grijalva CG, Zhu Y, Szilagyi P. The burden of respiratory syncytial virus infection in young children. N Engl J Med. 2009 Feb 5;360(6):588-98. doi: 10.1056/NEJMoa0804877.
citation: Wassmer SC, Lepolard C, Traore B, Pouvelle B, Gysin J, Grau GE. Platelets reorient Plasmodium falciparum-infected erythrocyte cytoadhesion to activated endothelial cells. J Infect Dis. 2004 Jan 15;189(2):180-9. doi: 10.1086/380761. Epub 2004 Jan 9.
citation: Callen A, Diener-West M, Zeitlin PL, Rubenstein RC. A simplified cyclic adenosine monophosphate-mediated sweat rate test for quantitative measure of cystic fibrosis transmembrane regulator (CFTR) function. J Pediatr. 2000 Dec;137(6):849-55. doi: 10.1067/mpd.2000.109198.
citation: Falsey AR, Hennessey PA, Formica MA, Cox C, Walsh EE. Respiratory syncytial virus infection in elderly and high-risk adults. N Engl J Med. 2005 Apr 28;352(17):1749-59. doi: 10.1056/NEJMoa043951.
citation: Joury J, Al Kaabi N, Al Dallal S, Mahboub B, Zayed M, Abdelaziz M, Onwumeh-Okwundu J, Fletcher MA, Kumaresan S, Ramachandrachar BC, Farghaly M. Retrospective Analysis of RSV Infection in Pediatric Patients: Epidemiology, Comorbidities, Treatment, and Costs in Dubai (2014-2023). J Health Econ Outcomes Res. 2024 Nov 5;11(2):133-144. doi: 10.36469/001c.123889. eCollection 2024.
citation: Nair H, Nokes DJ, Gessner BD, Dherani M, Madhi SA, Singleton RJ, O'Brien KL, Roca A, Wright PF, Bruce N, Chandran A, Theodoratou E, Sutanto A, Sedyaningsih ER, Ngama M, Munywoki PK, Kartasasmita C, Simoes EA, Rudan I, Weber MW, Campbell H. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010 May 1;375(9725):1545-55. doi: 10.1016/S0140-6736(10)60206-1.